Interferons α and β in cancer: therapeutic opportunities from new insights (Q91212056)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

20 April 2020

title

Interferons α and β in cancer: therapeutic opportunities from new insights (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

20 April 2020

author name string

Ernest C Borden

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

20 April 2020

publication date

1 March 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

20 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

20 April 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

20 April 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

20 April 2020

page(s)

219-234

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

Interferons at age 50: past, current and future impact on biomedicine

20 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Increased survival in mice inoculated with tumor cells and treated with interferon preparations

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferons: Rationale for Clinical Trials in Neoplastic Disease

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Clinical and laboratory investigations on man: systemic administration of potent interferon to man.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Leukocyte Interferon-Induced Tumor Regression in Human Metastatic Breast Cancer, Multiple Myeloma, and Malignant Lymphoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Progress toward therapeutic application of interferons, 1979–1983

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Beta-interferon for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferons: Success in anti-viral immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferons and viruses: an evolutionary arms race of molecular interactions

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Toxicities of Immunotherapy for the Practitioner

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Gene Modulatory Effects, Pharmacokinetics, and Clinical Tolerance of Interferon-α1b: A Second Member of the Interferon-α Family

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The untold story of IFN-γ in cancer biology.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IFN-λ cancer immunotherapy: new kid on the block

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STING: infection, inflammation and cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Innate immune sensing and signaling of cytosolic nucleic acids

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The IRF family transcription factors at the interface of innate and adaptive immune responses

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The AIM2-like Receptors Are Dispensable for the Interferon Response to Intracellular DNA.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IFI16 and cGAS cooperate in the activation of STING during DNA sensing in human keratinocytes.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IFI16 is required for DNA sensing in human macrophages by promoting production and function of cGAMP

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Crosstalk between Cytoplasmic RIG-I and STING Sensing Pathways

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Viral RNA detection by RIG-I-like receptors

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The anticancer functions of RIG-I-like receptors, RIG-I and MDA5, and their applications in cancer therapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

RIG-I: a multifunctional protein beyond a pattern recognition receptor

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The host STING pathway at the interface of cancer and immunity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cutting Edge: Activation of STING in T Cells Induces Type I IFN Responses and Cell Death.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

cGAS is essential for the antitumor effect of immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Host type I IFN signals are required for antitumor CD8 T cell responses through CD8{alpha} dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

A STING-activating nanovaccine for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

In vitro potentiation of radiation cytotoxicity by recombinant interferons in cervical cancer cell lines

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Mitotic progression following DNA damage enables pattern recognition within micronuclei.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Differential regulation of human blood dendritic cell subsets by IFNs

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I interferons in anticancer immunity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Plasmacytoid pre-dendritic cells (pDC) from molecular pathways to function and disease association

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

On taking the STING out of immune activation.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Expression of CCR-7, MIP-3beta , and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon alpha increases the frequency of interferon gamma-producing human CD4 T cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Chemokine expression in melanoma metastases associated with CD8 T-cell recruitment

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Innate immune signaling and regulation in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Self-priming determines high type I IFN production by plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The multifaceted biology of plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

TRAIL Human Plasmacytoid Dendritic Cells Kill Tumor Cells In Vitro: Mechanisms of Imiquimod- and IFN-α–Mediated Antitumor Reactivity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Absence of Stat1 in donor CD4 T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Impaired IFN- Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Divergent effects of type-I interferons on regulatory T cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

APC activation by IFN-alpha decreases regulatory T cell and enhances Th cell functions

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I IFN gene delivery suppresses regulatory T cells within tumors

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Low doses of interferon alpha result in more effective clinical natural killer cell activation

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I IFN contributes to NK cell homeostasis, activation, and antitumor function

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STING in tumor and host cells cooperatively work for NK cell-mediated tumor growth retardation.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The Essential Role of Type I Interferons in Differentiation and Activation of Tumor-Associated Neutrophils

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

A New Molecular Mechanism Underlying the Antitumor Effect of DNA Methylation Inhibitors via an Antiviral Immune Response

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Combining Epigenetic and Immunotherapy to Combat Cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Responses to Cytokines and Interferons that Depend upon JAKs and STATs

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The JAK-STAT pathway at twenty

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Fine tuning type I interferon responses

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferons and their stimulated genes in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferome v2.0: an updated database of annotated interferon-regulated genes

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-stimulated genes: a complex web of host defenses

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Endogenous type I interferons as a defense against tumors.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

A critical function for type I interferons in cancer immunoediting

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Enhanced tumor development in mice lacking a functional type I interferon receptor

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

A signature of immune function genes associated with recurrence-free survival in breast cancer patients

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Copy number loss of the interferon gene cluster in melanomas is linked to reduced T cell infiltrate and poor patient prognosis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Modulation of antitumour immune responses by intratumoural Stat1 expression

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Host STAT2/type I interferon axis controls tumor growth

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The Guanylate-Binding Proteins: Emerging Insights into the Biochemical Properties and Functions of This Family of Large Interferon-Induced Guanosine Triphosphatase

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Emerging Roles of FAM14 Family Members (G1P3/ISG 6–16 and ISG12/IFI27) in Innate Immunity and Cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

A death-promoting role for ISG54/IFIT2

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-stimulated gene 15 induces cancer cell death by suppressing the NF-κB signaling pathway

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Apoptotic properties of the type 1 interferon induced family of human mitochondrial membrane ISG12 proteins.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

ISG15 inhibits cancer cell growth and promotes apoptosis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Dynamic control of type I IFN signalling by an integrated network of negative regulators

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Negative regulation of type I IFN signaling

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Chromosomal instability drives metastasis through a cytosolic DNA response

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Therapeutic activity of high-dose intratumoral IFN-β requires direct effect on the tumor vasculature.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IFN-alpha induces transcription of hypoxia-inducible factor-1alpha to inhibit proliferation of human endothelial cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Gene Regulatory and Clinical Effects of Interferon β in Patients with Metastatic Melanoma: A Phase II Trial

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor α (TNFα) and interferon α (IFNα).

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STAT1 represses hypoxia-inducible factor-1-mediated transcription

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-beta prevents the upregulation of interleukin-8 expression in human melanoma cells

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon alfa-2a therapy for life-threatening hemangiomas of infancy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

AIDS-associated Kaposi's sarcoma: is there still a role for interferon alfa?

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Seamless Oncology-Drug Development.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Genetic variation in RNASEL associated with prostate cancer risk and progression

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Influence of genetic variants in type I interferon genes on melanoma survival and therapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) as a prognostic marker for local control in T1-2 N0 breast cancer treated with breast-conserving surgery and radiation therapy (BCS RT).

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

High IFIT1 expression predicts improved clinical outcome, and IFIT1 along with MGMT more accurately predicts prognosis in newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Inhibition of tumor cell motility by the interferon-inducible GTPase MxA

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Evolutionary Origins of cGAS-STING Signaling

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

cGAS surveillance of micronuclei links genome instability to innate immunity

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

GBP-1 acts as a tumor suppressor in colorectal cancer cells.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin alpha4 expression.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Guanylate-binding protein 1 expression from embryonal endothelial progenitor cells reduces blood vessel density and cellular apoptosis in an axially vascularised tissue-engineered construct

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The human interferons—From protein purification and sequence to cloning and expression in bacteria: Before, between, and beyond

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Recombinant Leukocyte A Interferon: Pharmacokinetics, Single-Dose Tolerance, and Biologic Effects in Cancer Patients

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

An overview on Vadimezan (DMXAA): The vascular disrupting agent

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Type I interferon in the pathogenesis of lupus

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Activated STING in a vascular and pulmonary syndrome

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

IFITM1 promotes the metastasis of human colorectal cancer via CAV-1.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Interferon-induced transmembrane protein 1-mediated EGFR/SOX2 signaling axis is essential for progression of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

Immunoregulatory properties of ISG15, an interferon-induced cytokine

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

ISG15 in cancer: Beyond ubiquitin-like protein

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.

1 reference

https://api.crossref.org/works/10.1038/S41573-018-0011-2

7 January 2021

10.1038/S41573-018-0011-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30679806 AND SRC:MED&resulttype=core&format=json

20 April 2020

1 reference